In 2017, Xu and collaborators registered a second clinical trial (ChiCTR-INR-17012462; Table 2), where 63 refractory patients with RA were treated with UC-derived MSCs combined with recombinant IFN-γ. The gene discussed is IFNG; the disease is rheumatoid arthritis.